Back to Newsroom

Novavax Initiates Phase 2 Clinical Trial of RSV Vaccine in Elderly Subjects

Gaithersburg, MD (October 14, 2014)–/GlobeNewswire/-Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 2 clinical trial of its respiratory syncytial virus (RSV) F-protein nanoparticle vaccine candidate (RSV F Vaccine), in healthy elderly subjects.

Click here to read more